Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.
Fernández-Nebro
Antonio
A
Rheumatology Section, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29010 Málaga, Spain. afn@mail.cofaran.es
Tomero
Eva
E
Ortiz-Santamaría
Vera
V
Castro
María Carmen
MC
Olivé
Alejandro
A
de Haro
Manuel
M
Portales
Rosa García
RG
García-Vicuña
Rosa
R
González-Mari
María Victoria
MV
Laffón
Armando
A
García-Vicuña
Rosario
R
D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013030:Spain / Q000453:epidemiology; D013167:Spondylitis, Ankylosing / Q000150:complications / Q000188:drug therapy / Q000401:mortality; D015996:Survival Rate; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept